• Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights

  • Community Resources

  • Our Expert Network

CME & EducationAbout Us
Loading...
CME & EducationAbout Us
Loading profile...
  • Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights
  • Community Resources

  • Our Expert Network
  1. Home
  2. Videos
  3. Discourses In Dermatology
  4. Tips For Managing Hair Loss Disorders In Pediatric Patients

Tips for Managing Hair Loss Disorders in Pediatric Patients

Featuring:
E(Elizabeth (Lisa) Swanson, MDFaculty
Updated:Sep 10, 2024
Pediatric DermatologyAlopecia

About this video

Hair loss in pediatric patients can be particularly challenging, both for the child and their family. In this episode of Topical Conversations, pediatric dermatologist Lisa Swanson, MD, shares 3 practical tips to help dermatologists effectively diagnose and manage the most common forms of hair loss in children.

  1. Recognize tinea capitis as a leading cause of alopecia with scaling 

    When faced with a child presenting alopecia and scalp scaling, dermatologists should assume tinea capitis (scalp ringworm) until proven otherwise. Tinea capitis is a fungal infection that requires prompt treatment to prevent worsening of symptoms and further hair loss. Dr Swanson emphasizes: 

    1. Oral antifungals are essential: Topical treatments alone will not resolve the infection. First-line therapies include oral terbinafine or griseofulvin, both highly effective against the dermatophyte fungi that cause tinea capitis. 
  2. Address loose anagen syndrome (LAS) in young children 

    Loose anagen syndrome (LAS) is another common cause of hair loss in young children, particularly females aged 3 to 4 who have never needed a haircut, with hair that rarely grows past their shoulders. LAS is characterized by hair that easily pulls out of the scalp due to improper anchoring in the follicle during the anagen phase. Dr Swanson offers several key points for managing LAS: 

    1. Reassure families: While concerning, LAS is typically a benign condition that often improves with age. Dr Swanson reassures parents that if their child is to experience hair loss, LAS is relatively mild, as it usually resolves spontaneously over time. 
    2. Psychological impact: Despite its benign nature, LAS can still be distressing for children, particularly young girls who may struggle with short or thinning hair. Dermatologists should address this emotional aspect by providing families with reassurance and information on the condition’s self-limiting nature. 
  3. Take alopecia areata (AA) seriously in pediatric patients 

    Alopecia areata in children is an autoimmune condition with significant psychosocial consequences. Dr Swanson urges dermatologists to approach treatment for pediatric AA with the same seriousness as they would for adult patients, emphasizing that early intervention can make a profound difference. Key treatment strategies include: 

    1. Topical corticosteroids and minoxidil foam: For younger children, intralesional corticosteroids are often avoided. Instead, Dr Swanson recommends topical corticosteroids, often combined with over-the-counter minoxidil foam to stimulate hair growth. 
    2. Pulse prednisone therapy: In certain cases, Dr Swanson suggests considering pulse prednisone therapy, where a large dose of prednisone is administered for one weekend a month. This regimen can help manage inflammation and potentially slow the progression of AA. 
    3. Low-dose oral minoxidil: For more severe or unresponsive cases, low-dose oral minoxidil may be used alongside pulse prednisone therapy to promote hair regrowth. 
    4. Off-label JAK inhibitors: In cases of severe or extensive AA, Dr Swanson highlights the potential use of oral JAK inhibitors for pediatric patients, although currently, no JAK inhibitors are FDA-approved for children under 12. However, she notes that dermatologists can work with insurance to obtain off-label approval for this treatment, which may offer life-changing results for certain patients. 

Hair loss disorders in pediatric patients require a careful, individualized approach. By promptly diagnosing conditions like tinea capitis and appropriately managing others, such as LAS and AA, dermatologists can significantly improve both the clinical outcomes and quality of life for their young patients.

1
Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma
5:04

Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma

2
What Changes When We Treat Psoriasis as Systemic Disease?
7:01

What Changes When We Treat Psoriasis as Systemic Disease?

3
Who to Look for and When to Act
2:31

Who to Look for and When to Act

4
How Oral TYK2 Inhibition Is Showing Up in Real Decisions
10:38

How Oral TYK2 Inhibition Is Showing Up in Real Decisions

5
Injecting on Bone: A Practical Approach to Filler Safety
0:44

Injecting on Bone: A Practical Approach to Filler Safety

6
Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study
8:12

Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study

7
Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course
2:51

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

8
Fast Relief, Sustained Control: What Remibrutinib Shows in CSU
2:42

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

9
Bullous Pemphigoid: The Evolving Treatment Landscape
8:22

Bullous Pemphigoid: The Evolving Treatment Landscape

10
Confirming BP Diagnosis and Choosing Treatment
7:42

Confirming BP Diagnosis and Choosing Treatment

11
How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC
4:08

How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC

12
What Four Years Can Tell Us About Treating Moderate to Severe HS
3:29

What Four Years Can Tell Us About Treating Moderate to Severe HS

13
Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib
3:18

Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib

14
A Review of Dermoscopy Techniques With Michelle Tarbox, MD
1:28

A Review of Dermoscopy Techniques With Michelle Tarbox, MD

15
Leading With Intention in Aesthetic Assessment
2:57

Leading With Intention in Aesthetic Assessment

16
Recognizing Bullous Pemphigoid Earlier in Clinical Practice
1:52

Recognizing Bullous Pemphigoid Earlier in Clinical Practice

17
Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration
10:34

Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration

18
Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso
23:00

Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso

19
Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma
8:33

Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma

20
Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test
6:53

Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test

21
Topical Truths: Managing AD in the Real World
21:54

Topical Truths: Managing AD in the Real World

22
The Oral Conversation: How We Talk to Patients About Systemic Therapy Today
30:51

The Oral Conversation: How We Talk to Patients About Systemic Therapy Today

23
Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice
10:00

Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice

24
Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk
10:04

Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk

25
Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways
9:36

Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways

26
Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients
9:51

Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients

27
Fall Clinical Continuity Experience - Vtama - Lecture Recap Video
0:35

Fall Clinical Continuity Experience - Vtama - Lecture Recap Video

28
Four Years of Data: Durability and Distinction with TYK2 Inhibition
3:09

Four Years of Data: Durability and Distinction with TYK2 Inhibition

29
What an Oral Option Means for Psoriasis Care
2:34

What an Oral Option Means for Psoriasis Care

30
LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults
8:39

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

31
Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes
7:58

Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes

32
Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis
4:59

Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis

33
VTAMA: A New Standard in Psoriasis Management
4:59

VTAMA: A New Standard in Psoriasis Management

34
Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions
18:17

Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions

35
Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice
16:27

Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice

36
Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing
6:45

Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing

37
Psoriasis mechanism of disease: Pathogenesis
8:27

Psoriasis mechanism of disease: Pathogenesis

38
Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors
12:45

Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors

Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved